Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease
Katharina Staufer, Ursula Huber-Schönauer, Georg Strebinger, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 918-930
Open Access | Times Cited: 127

Showing 1-25 of 127 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 281
Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 280
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming‐Hua Zheng, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S17-S31
Open Access | Times Cited: 233
Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease
Fredrik Åberg, Christopher D. Byrne, Carlos J. Pirola, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 191-206
Open Access | Times Cited: 149
Alcohol-Associated Hepatitis
Ramón Bataller, Juan Pablo Arab, Vijay H. Shah
New England Journal of Medicine (2022) Vol. 387, Iss. 26, pp. 2436-2448
Closed Access | Times Cited: 143
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 764-783
Closed Access | Times Cited: 93
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature
Brian P. Lee, Jennifer L. Dodge, Norah A. Terrault
Hepatology (2023) Vol. 79, Iss. 3, pp. 666-673
Open Access | Times Cited: 83
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study
Mads Israelsen, Nikolaj Torp, Stine Johansen, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 3, pp. 218-228
Open Access | Times Cited: 66
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 54
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Paul Brennan, Ahmed M. Elsharkawy, Timothy J. Kendall, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 679-688
Open Access | Times Cited: 50
Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease
Rohit Loomba, Vincent Wai‐Sun Wong
Alimentary Pharmacology & Therapeutics (2023) Vol. 59, Iss. 2, pp. 150-156
Open Access | Times Cited: 49
Aetiology of liver disease and response to immune checkpoint inhibitors: An updated meta-analysis confirms benefit in those with non-viral liver disease
Tim Meyer, Sevasti Galani, Andre Lopes, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. e73-e76
Closed Access | Times Cited: 46
MetALD: new opportunities to understand the role of alcohol in steatotic liver disease
Mads Israelsen, Nikolaj Torp, Stine Johansen, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 866-868
Closed Access | Times Cited: 43
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hannes Hagström, Ying Shang, Hannes Hegmar, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 944-956
Closed Access | Times Cited: 33
Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease
David Martí‐Aguado, José Luís Calleja, Eduardo Vilar‐Gómez, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 6, pp. 930-940
Closed Access | Times Cited: 30
Steatotic liver disease
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 26
Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis
Patrik Nasr, Axel Wester, Mattias Ekstedt, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 5, pp. 1048-1057.e2
Open Access | Times Cited: 21
Metabolic Dysfunction and Alcohol-related Liver Disease (MetALD): Position statement by an expert panel on alcohol-related liver disease
Juan Pablo Arab, Luis Antonio Díaz, Jürgen Rehm, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 21
Inequities in primary liver cancer in Europe: The state of play
Loreta A. Kondili, Jeffrey V. Lazarus, Peter Jepsen, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 4, pp. 645-660
Open Access | Times Cited: 19
Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019
Pojsakorn Danpanichkul, Majd B. Aboona, Banthoon Sukphutanan, et al.
Hepatology (2024) Vol. 80, Iss. 4, pp. 828-843
Closed Access | Times Cited: 19
Polysaccharides from Chinese herbal medicine: a review on the hepatoprotective and molecular mechanism
Jifeng Li, Haolin Guo, Ying Dong, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 1, pp. 4-14
Closed Access | Times Cited: 17
Impact of MASLD and MetALD on clinical outcomes: A meta‐analysis of preliminary evidence
Stefano Ciardullo, Alessandro Mantovani, Mario Luca Morieri, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1762-1767
Closed Access | Times Cited: 16
Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
Pojsakorn Danpanichkul, Vincent Chen, Primrose Tothanarungroj, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 3, pp. 378-388
Closed Access | Times Cited: 16
Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
Federica Tavaglione, Maral Amangurbanova, Alexander H. Yang, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 8
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Vlad Ratziu, Scott L. Friedman
Gastroenterology (2020) Vol. 165, Iss. 1, pp. 5-10
Closed Access | Times Cited: 71
Page 1 - Next Page

Scroll to top